B-intervention	0	10	Zoledronic
I-intervention	11	15	acid
O	16	24	prevents
O	25	31	cancer
O	32	41	treatment
O	41	42	-
O	42	49	induced
B-condition	50	54	bone
I-condition	55	59	loss
O	60	62	in
B-eligibility	63	76	premenopausal
I-eligibility	77	82	women
I-eligibility	83	92	receiving
I-eligibility	93	101	adjuvant
I-eligibility	102	111	endocrine
I-eligibility	112	119	therapy
I-eligibility	120	123	for
I-eligibility	124	131	hormone
I-eligibility	131	132	-
I-eligibility	132	142	responsive
I-eligibility	143	149	breast
I-eligibility	150	156	cancer
O	156	157	:
O	158	159	a
O	160	166	report
O	167	171	from
O	172	175	the
B-location	176	184	Austrian
O	185	191	Breast
O	192	195	and
O	196	206	Colorectal
O	207	213	Cancer
O	214	219	Study
O	220	225	Group
O	225	226	.

O	227	235	Adjuvant
O	236	243	therapy
O	244	247	for
O	248	254	breast
O	255	261	cancer
O	262	265	can
O	266	268	be
O	269	279	associated
O	280	284	with
O	285	294	decreased
O	295	299	bone
O	300	307	mineral
O	308	315	density
O	316	317	(
O	317	320	BMD
O	320	321	)
O	322	326	that
O	327	330	may
O	331	335	lead
O	336	338	to
O	339	347	skeletal
O	348	357	morbidity
O	357	358	.

O	359	363	This
O	364	369	study
O	370	378	examined
O	379	386	whether
O	387	397	zoledronic
O	398	402	acid
O	403	406	can
O	407	414	prevent
O	415	419	bone
O	420	424	loss
O	425	435	associated
O	436	440	with
O	441	449	adjuvant
O	450	459	endocrine
O	460	467	therapy
O	468	470	in
O	471	484	premenopausal
O	485	493	patients
O	493	494	.

O	495	499	This
O	500	505	study
O	506	508	is
O	509	510	a
O	511	521	randomized
O	521	522	,
O	523	527	open
O	527	528	-
O	528	533	label
O	533	534	,
O	535	540	phase
O	541	544	III
O	544	545	,
O	546	550	four
O	550	551	-
O	551	554	arm
O	555	560	trial
O	561	570	comparing
B-intervention	571	580	tamoxifen
O	581	582	(
O	582	584	20
O	585	587	mg
O	587	588	/
O	588	589	d
O	590	596	orally
O	596	597	)
O	598	601	and
B-intervention	602	611	goserelin
O	612	613	(
O	613	614	3
O	614	615	.
O	615	616	6
O	617	619	mg
O	620	625	every
O	626	628	28
O	629	633	days
O	634	648	subcutaneously
O	648	649	)
O	650	651	+
O	651	652	/
O	652	653	-
O	654	664	zoledronic
O	665	669	acid
O	670	671	(
O	671	672	4
O	673	675	mg
O	676	689	intravenously
O	690	695	every
O	696	697	6
O	698	704	months
O	704	705	)
O	706	712	versus
B-intervention	713	724	anastrozole
O	725	726	(
O	726	727	1
O	728	730	mg
O	730	731	/
O	731	732	d
O	733	739	orally
O	739	740	)
O	741	744	and
O	745	754	goserelin
O	755	756	+
O	756	757	/
O	757	758	-
O	759	769	zoledronic
O	770	774	acid
O	775	778	for
O	779	780	3
O	781	786	years
O	787	789	in
O	790	803	premenopausal
O	804	809	women
O	810	814	with
O	815	822	hormone
O	822	823	-
O	823	833	responsive
O	834	840	breast
O	841	847	cancer
O	847	848	.

O	849	851	In
O	852	853	a
O	854	857	BMD
O	858	869	subprotocol
O	870	872	at
O	873	878	three
O	879	884	trial
O	885	892	centers
O	892	893	,
O	894	902	patients
O	903	912	underwent
O	913	919	serial
O	920	923	BMD
O	924	936	measurements
O	937	939	at
O	940	941	0
O	941	942	,
O	943	944	6
O	944	945	,
O	946	948	12
O	948	949	,
O	950	952	24
O	952	953	,
O	954	957	and
O	958	960	36
O	961	967	months
O	967	968	.

B-total-participants	969	973	Four
I-total-participants	974	981	hundred
I-total-participants	982	985	one
O	986	994	patients
O	995	999	were
O	1000	1008	included
O	1009	1011	in
O	1012	1015	the
O	1016	1019	BMD
O	1020	1031	subprotocol
O	1031	1032	.

O	1033	1042	Endocrine
O	1043	1052	treatment
O	1053	1060	without
O	1061	1071	zoledronic
O	1072	1076	acid
O	1077	1080	led
O	1081	1083	to
O	1084	1095	significant
O	1096	1097	(
O	1097	1098	P
O	1099	1100	<
O	1101	1102	.
O	1102	1105	001
O	1105	1106	)
B-outcome	1107	1114	overall
I-outcome	1115	1119	bone
I-outcome	1120	1124	loss
O	1125	1130	after
O	1131	1132	3
O	1133	1138	years
O	1139	1141	of
O	1142	1151	treatment
O	1152	1153	(
O	1153	1156	BMD
O	1156	1157	,
O	1158	1159	-
O	1159	1161	14
O	1161	1162	.
O	1162	1163	4
O	1163	1164	%
O	1165	1170	after
O	1171	1173	36
O	1174	1180	months
O	1180	1181	;
O	1182	1186	mean
O	1187	1188	T
O	1189	1194	score
O	1195	1204	reduction
O	1204	1205	,
O	1206	1207	-
O	1207	1208	1
O	1208	1209	.
O	1209	1210	4
O	1210	1211	)
O	1211	1212	.

B-outcome	1213	1220	Overall
I-outcome	1221	1225	bone
I-outcome	1226	1230	loss
O	1231	1234	was
O	1235	1248	significantly
O	1249	1253	more
O	1254	1260	severe
O	1261	1263	in
O	1264	1272	patients
O	1273	1282	receiving
O	1283	1294	anastrozole
O	1294	1295	/
O	1295	1304	goserelin
O	1305	1306	(
O	1306	1309	BMD
O	1309	1310	,
O	1311	1312	-
O	1312	1314	17
O	1314	1315	.
O	1315	1316	3
O	1316	1317	%
O	1317	1318	;
O	1319	1323	mean
O	1324	1325	T
O	1326	1331	score
O	1332	1341	reduction
O	1341	1342	,
O	1343	1344	-
O	1344	1345	2
O	1345	1346	.
O	1346	1347	6
O	1347	1348	)
O	1349	1357	compared
O	1358	1362	with
O	1363	1371	patients
O	1372	1381	receiving
O	1382	1391	tamoxifen
O	1391	1392	/
O	1392	1401	goserelin
O	1402	1403	(
O	1403	1406	BMD
O	1406	1407	,
O	1408	1409	-
O	1409	1411	11
O	1411	1412	.
O	1412	1413	6
O	1413	1414	%
O	1414	1415	;
O	1416	1420	mean
O	1421	1422	T
O	1423	1428	score
O	1429	1438	reduction
O	1438	1439	,
O	1440	1441	-
O	1441	1442	1
O	1442	1443	.
O	1443	1444	1
O	1444	1445	)
O	1445	1446	.

O	1447	1449	In
O	1450	1458	contrast
O	1458	1459	,
B-outcome	1460	1463	BMD
O	1464	1472	remained
O	1473	1479	stable
O	1480	1482	in
O	1483	1493	zoledronic
O	1494	1498	acid
O	1498	1499	-
O	1499	1506	treated
O	1507	1515	patients
O	1516	1517	(
O	1517	1518	P
O	1519	1520	<
O	1521	1522	.
O	1522	1526	0001
O	1527	1535	compared
O	1536	1540	with
O	1541	1550	endocrine
O	1551	1558	therapy
O	1559	1564	alone
O	1564	1565	)
O	1565	1566	.

O	1567	1569	No
O	1570	1582	interactions
O	1583	1587	with
O	1588	1591	age
O	1592	1594	or
O	1595	1600	other
O	1601	1605	risk
O	1606	1613	factors
O	1614	1618	were
O	1619	1624	noted
O	1624	1625	.

O	1626	1635	Endocrine
O	1636	1643	therapy
O	1644	1650	caused
O	1651	1662	significant
O	1663	1667	bone
O	1668	1672	loss
O	1673	1677	that
O	1678	1687	increased
O	1688	1692	with
O	1693	1702	treatment
O	1703	1711	duration
O	1712	1714	in
O	1715	1728	premenopausal
O	1729	1734	women
O	1735	1739	with
O	1740	1746	breast
O	1747	1753	cancer
O	1753	1754	.

O	1755	1765	Zoledronic
O	1766	1770	acid
O	1771	1772	4
O	1773	1775	mg
O	1776	1781	every
O	1782	1783	6
O	1784	1790	months
O	1791	1802	effectively
O	1803	1812	inhibited
O	1813	1817	bone
O	1818	1822	loss
O	1822	1823	.

O	1824	1831	Regular
O	1832	1835	BMD
O	1836	1848	measurements
O	1849	1852	and
O	1853	1863	initiation
O	1864	1866	of
O	1867	1878	concomitant
O	1879	1893	bisphosphonate
O	1894	1901	therapy
O	1902	1904	on
O	1905	1913	evidence
O	1914	1916	of
O	1917	1921	bone
O	1922	1926	loss
O	1927	1933	should
O	1934	1936	be
O	1937	1947	considered
O	1948	1951	for
O	1952	1960	patients
O	1961	1971	undergoing
O	1972	1981	endocrine
O	1982	1989	therapy
O	1989	1990	.
